Chemistry: molecular biology and microbiology – Virus or bacteriophage – except for viral vector or... – Inactivation or attenuation; producing viral subunits
Patent
1996-12-06
1999-03-09
Scheiner, Laurie
Chemistry: molecular biology and microbiology
Virus or bacteriophage, except for viral vector or...
Inactivation or attenuation; producing viral subunits
4353201, 4241991, 4242081, 4241881, C12N 704, C12N 1500, A61K 3912, A61K 3921
Patent
active
058799257
ABSTRACT:
Non-infectious, retrovirus-like particles comprise an assembly of an env gene product, a pol gene product and a gag gene product contain an antigenic marker which is non-retroviral or non-HIV retroviral. In one embodiment, the marker comprises an amino acid sequence containing an epitope inserted into the gag gene product at an antigenically-active insertion site. In another embodiment, the marker comprises an antigenic anchor sequence operatively connected to the env gene product replacing endogenous anchoring function. The corresponding nucleic acid molecules are described. The non-infectious, retrovirus-like particles have utility in in vivo administration including to humans and in diagnosis. The presence of the antigenic marker enables recognition that antiserum containing anti-retroviral antibodies has been generated by exposure to the non-infectious retrovirus-like particles by testing for antibodies specific to the antigenic marker.
REFERENCES:
Coffin, J., 1996, "Retroviridae: The Viruses and Their Replication" in Fields Virology, Third Edition, Fields et al., eds., Lippincott-Raven Publishers, Philadelphia, pp. 1767-1771.
Hunter, E., 1994, Sem. Virol. 5:71-83.
Karacostas et al., 1993, Virol. 193:661-671.
Rovinski et al., 1992, J. Virol. 66:4003-4012.
Perkins et al., 1991, J. Immunol. 146:2137-2144.
Sharma et al., 1993, Vaccine 11:1321-1326.
Rovinski, B., Haynes, J.R., Cao, S.X., James, O., Sia, C., Zolla-Pazner, S., Matthews, T.J. and Klein, M. (1992) J.Virol., 66, 4003-4012.
Wain-Hobson, S., Sonigo, P., Danos, O., Col, S. and Alizon, M. (1985) Cell, 40, 9-17.
Myers, G., Berzofsky, J.A., Rabson, A.B., Smith, T.F. and Wong-Staal, F. (ed.) (1990) Human retroviruses and Aids. Theoretical Biology and Biophysics, Group T-10. Los Alamos National Laboratory, Los Alamos, N.Mex.
Alizon, M., Sonigo, P., Barre-Sinoussi, F., Chermann, J.C., Tiollais, P., Montagnier, L. and Wain-Hobson, S. (1984) Nature, 312,757-780.
Min Jou, W., Verhoeyen, M., Devos, R., Saman, E., Fang, R., Huylebroeck, D. and Fiers, W. (1980) Cell, 19, 683-696.
Westhof, E., Altschuh, D., Moras, D., Bloomer, A.C., Mondragon, A., Klug, A. and Van Regenmortel, M.H. (1984) Nature, 311, 123-126.
Trifilleff, E., Dubs, M.C. and Regenmertel, M.H.V. (1991) Mol. Immunol., 28, 889-896.
Ulmer et al., 1993 current Drugs Ltd. ISSN 0967-8298.
Hunter, 1994, Sem. Virol. 5:71.
Karacostas et al. 1993, Virol. 193: 661-671.
Rovinski et al., 1992 J. Virol. 66: 4003-4012.
Perkins et al., 1991, J. Immunol. 146: 2137-2144.
Sharma et al. 1993, Vaccine 11: 1321-1326.
Haynes et al. 1991, AIDS Res. Human Retro. 7:17-27.
Zhao-Wen, 1980, Nuc. Acids Prot. Proc, Symp. 196-200.
Klein M., Aids Research and Human Retroviruses--vol. 10, Supplement 1, Aug. 1994--"Neutralizing activies of HIV-1 pseudovirions and T-B tandem epitopes".
Haynes J.R. et al., The vaccine Symposium, Toronto, Ontario, Canada, Oct. 1989. Molecular Immun. 28(3) 1991. pp. 231-234, "Strategy for Developing a Genetically-Engineered Whole-Virus Vaccine against HIV".
Karacostas, V. et al. Proceedigns of the National Academy of Sciences of the USA, vol. 86, No. 22 Nov. 1, 1989, "Immunodeficiency Virus-Like Particles Produced by a Vaccinia Virus Expression Vector".
Yao., Fei-Long et al. Biotechniques (1995), 18(3) pp. 372-374--Mar. 1995, Gene assembly-aided mutagenesis (GAAM).
Cao Shi-Xian
Klein Michel H.
Persson Roy
Rovinski Benjamin
Yao Fei-Long
Connaught Laboratories Limited
Parkin Jeffrey S.
Scheiner Laurie
LandOfFree
Genetically engineered human immunodeficiency virus-like particl does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genetically engineered human immunodeficiency virus-like particl, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetically engineered human immunodeficiency virus-like particl will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1319885